BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Cantor Fitzgerald
Baxter
Queensland Health
Daiichi Sankyo
US Department of Justice
Colorcon
McKesson
AstraZeneca
Express Scripts

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203756

« Back to Dashboard

NDA 203756 describes COMETRIQ, which is a drug marketed by Exelixis and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the COMETRIQ profile page.

The generic ingredient in COMETRIQ is cabozantinib s-malate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the cabozantinib s-malate profile page.
Summary for 203756
Tradename:COMETRIQ
Applicant:Exelixis
Ingredient:cabozantinib s-malate
Patents:3
Pharmacology for NDA: 203756
Mechanism of ActionProtein Kinase Inhibitors
Suppliers and Packaging for NDA: 203756
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
COMETRIQ cabozantinib s-malate CAPSULE;ORAL 203756 NDA Exelixis, Inc. 42388-011 42388-011-14 4 BLISTER PACK in 1 CARTON (42388-011-14) > 1 KIT in 1 BLISTER PACK
COMETRIQ cabozantinib s-malate CAPSULE;ORAL 203756 NDA Exelixis, Inc. 42388-012 42388-012-14 4 BLISTER PACK in 1 CARTON (42388-012-14) > 1 KIT in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 20MG BASE
Approval Date:Nov 29, 2012TE:RLD:Yes
Regulatory Exclusivity Expiration:Nov 29, 2017
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Nov 29, 2019
Regulatory Exclusivity Use:ORPHAN DRUG EXCLUSIVITY
Patent:➤ SubscribePatent Expiration:Aug 14, 2026Product Flag?YSubstance Flag?YDelist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Fish and Richardson
Baxter
Farmers Insurance
Chinese Patent Office
Argus Health
Chubb
Accenture
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot